



VIA HAND DELIVERY JULY 10, 2003

Docket No.: PF112U1  
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:  
Alderson et al.

Application No.: 09/499,468

Group Art Unit: 1647

Filed: February 7, 2000

Examiner: R. Landsman

For: Use of Vascular Endothelial Growth Factor 2 to  
Treat Photoreceptor Cells (as amended)

**EIGHTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

In accordance with the duty of disclosure imposed by 37 C.F.R. § 1.56 to inform the Patent and Trademark Office of all references coming to the attention of each individual associated with the filing or prosecution of the subject application, which are or may be material to the patentability of a claim of the subject application, Attorney for Applicants hereby directs the Examiner's attention to references GW-HC on the attached Form PTO/SB/08. No copies of references GW-HC are enclosed.

References GW-HB were previously cited as references BI-BN on Form PTO/SB/08 and submitted on the Information Disclosure Statement filed 11/29/01, and reference HC was previously cited as reference DV on Form PTO/SB/08 and submitted on the Information Disclosure Statement filed 11/29/01. Accordingly, no copies of these references are provided.

The listed references are presented so that the Patent and Trademark Office can determine any materiality thereof to the claimed invention. See 37 C.F.R. § 1.104(a) concerning the Examiner's duty to consider and use any such information. Applicants respectfully request that the Examiner make the listed references of record in the file history of the application, and consider the information contained therein during the prosecution of this application.

07/11/2003 HDAITE1 00000101 083425 09499468

02 FC:1806 180.00 DA

#22  
Dmt  
8-7-03

Identification of the listed references is not to be construed an admission of any individual associated with the filing or prosecution of the subject application that such references are available as "prior art" against the subject application. Furthermore, Applicants do not waive any rights to take appropriate action to establish patentability over any of the listed documents should they be applied as references against the claims of the subject application.

Pursuant to 37 C.F.R. § 1.97(c), because this Information Disclosure Statement is being submitted after the mailing date of the first Office Action on the merits, but before the mailing date of a Final Office Action, or a Notice of Allowance under 37 C.F.R. § 1.311, or an action that otherwise closes prosecution, the Patent and Trademark Office will consider this Information Disclosure Statement if it is accompanied by the fee as specified in 37 C.F.R. § 1.17(p).

Accordingly, the Patent & Trademark Office is hereby authorized to charge our Deposit Account No. 08-3425 in the amount of \$180.00 as payment of the required fee, as itemized on the Fee Transmittal Sheet submitted concurrently herewith.

The Commissioner is hereby authorized to charge any deficiency in the fees filed, or credit any overpayment, to our Deposit Account No. 08-3425.

Dated: July 10, 2003

Respectfully submitted,

By   
Michele M. Wales

Registration No.: 43,975  
HUMAN GENOME SCIENCES, INC.  
9410 Key West Avenue  
Rockville, Maryland 20850  
(301) 610-5772

Enclosure  
MW/lcc



PTO/SB/08a/b (05-03)  
Approved for use through 05/31/2003. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

<b>Substitute for form 1449/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		<b>Complete if Known</b>			
		Application Number	09/499,468		
		Filing Date	February 7, 2000		
		First Named Inventor	Ralph Alderson		
		Art Unit	1647		
		Examiner Name	R. Landsman		
Sheet	1	of	1	Attorney Docket Number	PF112U1

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
	GW	US-08/510,133	08/1995		
	GX	US-08/585,895	01/1996		
	GY	US-08/601,132	02/1996		
	GZ	US-08/671,573	06/1996		
	HA	US-60/003,491	09/1995		
	HB	US-08/554,374	11/1995		

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)	MM-DD-YYYY			

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the application number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		
	HC	LITWIN <i>et al.</i> , "Role of Cytokines in Endothelial Cell Functions," Human Growth factors: Their role in Disease and Therapy, BB Aggarwal & RK Puri (Eds), Blackwell Science, Inc. USA Chapter 7 101-129 (1995).		

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--